Contribute Try STAT+ Today

Agios Pharmaceuticals said Tuesday that its experimental drug mitapivat increased hemoglobin levels in patients with a rare form of anemia — achieving the primary goal of a Phase 3 clinical trial.

Mitapivat is the most important and closely followed medicine in Agios’ research pipeline because of its potential to treat a range of rare blood diseases defined by the destruction or malfunction of oxygen-carrying red blood cells. The positive study results announced Tuesday involved adults with pyruvate kinase deficiency, or PK deficiency. Agios is also developing mitapivat as a potential treatment for patients with sickle cell disease and two types of thalassemia.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.